Conferences

Conference Details

Overview: The last few years have seen an increase in product recalls. For this and other reasons, the U.S. FDA come under increasing negative public scrutiny. High profile drug recalls, food chain problems and contamination, import problems, resignations. Now a new commissioner vows no more business as usual. Data in submissions and decisions rendered will be more science-based and subjected to greater scrutiny. Failure to comply will result in more and faster Warning Letter filings. Larger, higher profile companies are coming under FDA investigation activities.

Date :

Place : United States, Fremont

Website :

Contact Person:Event Manager

Description:

Overview: The last few years have seen an increase in product recalls. For this and other reasons, the U.S. FDA come under increasing negative public scrutiny. High profile drug recalls, food chain problems and contamination, import problems, resignations. Now a new commissioner vows no more "business as usual". Data in submissions and decisions rendered will be more science-based and subjected to greater scrutiny. Failure to comply will result in more and faster Warning Letter filings. Larger, higher profile companies are coming under FDA investigation activities.

Overview: The last few years have seen an increase in product recalls. For this and other reasons, the U.S. FDA come under increasing negative public scrutiny. High profile drug recalls, food chain problems and contamination, import problems, resignations. Now a new commissioner vows no more business as usual. Data in submissions and decisions rendered will be more science-based and subjected to greater scrutiny. Failure to comply will result in more and faster Warning Letter filings. Larger, higher profile companies are coming under FDA investigation activities. will be held in Fremont,United States on date 2016-09-14

Deadline for abstracts/proposals : 13th September 2016

Organized By :Compliance4All

Keynote Speakers :

Venue :Fremont, CA, United States

Check the for more details.

Overview: The last few years have seen an increase in product recalls. For this and other reasons, the U.S. FDA come under increasing negative public scrutiny. High profile drug recalls, food chain problems and contamination, import problems, resignations. Now a new commissioner vows no more business as usual. Data in submissions and decisions rendered will be more science-based and subjected to greater scrutiny. Failure to comply will result in more and faster Warning Letter filings. Larger, higher profile companies are coming under FDA investigation activities.

Views: 580

Venue - Map & Directions